Mizuho Securities analyst Difei Yang maintained a Buy rating on Selecta Biosciences (SELB) today and set a price target of $30. The company’s shares opened today at $5.70, close to its 52-week low of $4.74.
Yang said:
“We do not see earnings as the most meaningful indicator of value for an early-stage biotech. More importantly, Selecta announced the prioritization of a head-to-head superiority trial vs. standard of care Krystexxa. The trial is expected to begin in 1Q19 with data available at 3-month and 6- month time points and we expect interim read outs at both. A capital raise is likely needed to conduct the trial. While shares have underperformed recently, we see risk/reward as highly favorable and remain buyers.”
According to TipRanks.com, Yang is a 5-star analyst with an average return of 19.8% and a 48.3% success rate. Yang covers the Healthcare sector, focusing on stocks such as Alder Biopharmaceuticals, Audentes Therapeutics, and Revance Therapeutics.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Selecta Biosciences with a $30 average price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $16.55 and a one-year low of $4.74. Currently, Selecta Biosciences has an average volume of 222.2K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Selecta Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The firm produces the Synthetic Vaccine Particles (SVP) platform for immune tolerance and immune stimulation.
